87013-80-7Relevant articles and documents
Aryl-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives bearing a sulfonamide moiety show single-digit nanomolar-to-subnanomolar inhibition constants against the tumor-associated human carbonic anhydrases IX and XII
Ceruso, Mariangela,Gratteri, Paola,Hargunani, Priya,Kazaks, Andris,Leitans, Janis,Nocentini, Alessio,Supuran, Claudiu T.,Tadge, Nikhil,Tars, Kaspars,Toraskar, Mrunmayee P.
, (2020/04/27)
A series of new 3-phenyl-5-aryl-N-(4-sulfamoylphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives was designed here, synthesized, and studied for carbonic anhydrase (CAs, EC 4.2.1.1) inhibitory activity against the human (h) isozymes I, II, and VII (cytosolic, off-target isoforms), and IX and XII (anticancer drug targets). Generally, CA I was not effectively inhibited, whereas effective inhibitors were identified against both CAs II (KIs in the range of 5.2-233 nM) and VII (KIs in the range of 2.3-350 nM). Nonetheless, CAs IX and XII were the most susceptible isoforms to this class of inhibitors. In particular, compounds bearing an unsubstituted phenyl ring at the pyrazoline 3 position showed 1.3-1.5 nM KIs against CA IX. In contrast, a subset of derivatives having a 4-halo-phenyl at the same position of the aromatic scaffold even reached subnanomolar KIs against CA XII (0.62-0.99 nM). Docking studies with CA IX and XII were used to shed light on the derivative binding mode driving the preferential inhibition of the tumor-associated CAs. The identified potent and selective CA IX/XII inhibitors are of interest as leads for the development of new anticancer strategies.
Carbonic anhydrase inhibitors: Design, synthesis, and biological evaluation of novel sulfonyl semicarbazide derivatives
Pichake, Jayashree,Kharkar, Prashant S.,Ceruso, Mariangela,Supuran, Claudiu T.,Toraskar, Mrunmayee P.
, p. 793 - 796 (2014/08/05)
A series of novel sulfonyl semicarbazides 5-13 was designed, synthesized, and evaluated for human carbonic anhydrase (hCA) inhibition. The new sulfonyl semicarbazides were tested against a panel of hCA isoforms I, II, IX, and XII, using acetazolamide (AZA
4-Sulphamoylphenyl semicarbazones with anticonvulsant activity
Yogeeswari,Sriram,N.pandeya,Stables
, p. 609 - 613 (2007/10/03)
A series of 4-sulphamoylphenyl semicarbazone derivatives were prepared starting from sulphanilamide and screened for anticonvulsant activity. The results indicated that greater protection was obtained in the maximal electroshock screen (MES) and subcutane
